Registry update — unassessed
An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 19, 2023 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report sample size, so the statistical power to detect effects is unknown. The abstract does not report any effect sizes or results, preventing assessment of whether the intervention actually produced detectable epigenetic changes. Findings from localized skin application cannot be generalized to systemic aging or whole-body health outcomes.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Epigenetic changes in the skin
- Effect size
- —
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Jul 19, 2023
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Title: An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)
Journal: The University of Texas Health Science Center at San Antonio
Abstract: Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.